Sensorion's Gene Therapy Presentation at 2025 ASPO Annual Meeting

Sensorion, a biotechnology company focused on hearing loss therapies, announced that Professor Natalie Loundon will present at the American Society of Pediatric Otolaryngology's annual meeting. The event will take place in Montreal, Canada, from April 30 to May 3, 2025.

Professor Loundon's presentation is scheduled for May 1st at 4.20 pm CET. Her talk will cover "Principle and Practice of a Gene Therapy for Hearing loss," focusing on the SENS-501 clinical trial for children with hearing loss due to OTOF gene mutations. This Phase 1/2 trial, named Audiogene, explores the safety and efficacy of SENS-501 in young children.

The study, targeting infants and toddlers, aims to maximize speech and language acquisition through gene therapy during optimal brain plasticity periods. Sensorion's trial investigates safety through dosage escalation and auditory response as primary endpoints.